# AL-605

Source: https://onco.cc/drugs/al-605/  
OnCo record `al-605` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AL-605 is an experimental small molecule from Alaw Therapeutics, in phase 1 trials for HR-positive breast cancer after CDK4/6 inhibitors with CCNE1 amplification or overexpression, CCNE1-amplified ovarian cancer and endometrial cancer and other cancers.

## Summary

AL-605 is a small molecule from Alaw Therapeutics. A selective, brain-penetrant CDK2 inhibitor designed to target CDK2-dependent tumour growth, including cyclin E-driven cancers and settings where CDK2 activation drives resistance. Its furthest stage is phase 1, for HR-positive breast cancer after CDK4/6 inhibitors with CCNE1 amplification or overexpression, CCNE1-amplified ovarian cancer, endometrial cancer and gastric cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Company release of 29 May 2026: first patients dosed in a phase 1a/b trial in CCNE1-amplified solid tumours; interim data expected in the second half of 2026. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline
- Code: AL-605
- Modality: Small molecule
- Mechanism: A selective, brain-penetrant CDK2 inhibitor designed to target CDK2-dependent tumour growth, including cyclin E-driven cancers and settings where CDK2 activation drives resistance.

## Sources

- Alaw Therapeutics: alawtx.com: https://www.alawtx.com/pipeline
- Alaw Therapeutics: alawtx.com: https://www.alawtx.com/news1/alaw-therapeutics-announces-two-major-pipeline-milestones-advancing-brain-penetrant-cdk-oncology-programs

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CDK2](https://onco.cc/targets/cdk2/)
- companies: [Alaw Therapeutics](https://onco.cc/companies/alaw-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/al-605.json